Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohsin Qayyum

Psychiatry Sugar Land, TX Medical Doctor

NPI 1710942727 CMS profile 78040

7002 Riverbrook Dr Ste 800, Suite # B, Sugar Land, TX 77479

Open in the dashboard

General payments

$241

16 records reported · program years 2019–2025

Research payments

$285,523

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohsin Qayyum of Sugar Land, TX is reported in the CMS Open Payments database as having received $241 across 16 general payments and $285,523 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2025 Research $285,523 12
2024 General $19 1
2023 General $54 2
2020 General $18 1
2019 General $134 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohsin Qayyum
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mohsin Qayyum were reported at $16. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mohsin Qayyum Psychiatry median Middle half National median
2019 $134 $184 $59–$605 $163
2020 $18 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $54 $170 $56–$651 $160
2024 $19 $179 $57–$673 $164
2025 $16 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $126 6 payments
  2. Sunovion Pharmaceuticals Inc. $69 7 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $19 1 payment
  4. E.R. Squibb & Sons, L.L.C. $16 1 payment
  5. Teva Pharmaceuticals USA, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $241 16 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $126 6 payments
  2. INVEGA TRINZA $72 3 payments
  3. LATUDA $69 7 payments
  4. Kerendia $19 1 payment
  5. SPRAVATO $18 1 payment
  6. COBENFY $16 1 payment
  7. AUSTEDO $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Imbrium Therapeutics L.P. $285,523 12 payments

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$22,643

Medicare's payments for the services billed

Medicare patients

178

Average age 57

Services billed

206

81 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 74%
High blood pressure 71%
Diabetes 39%
Alzheimer's or dementia 31%
Arthritis 28%
Chronic kidney disease 24%
Ischemic heart disease 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record